Goldman Sachs Maintains Neutral on GeneDx Hldgs, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on GeneDx Hldgs (NASDAQ:WGS) and lowered the price target from $7 to $6.
November 01, 2023 | 1:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on GeneDx Hldgs and lowered the price target from $7 to $6.
The lowering of the price target by Goldman Sachs from $7 to $6 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100